Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KH631 gene therapy in neovascular age-related macular degeneration
NCT05657301Phase 1Active, not recruiting
- Sponsor
- Chengdu Origen Biotechnology Co., Ltd.
- Start
- Oct 2023
- Primary completion
- Sep 2026
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
Phase 1, open-label trial of KH631 in neovascular age-related macular degeneration (NVAMD) (5 arms), sponsored by Chengdu Origen Biotechnology Co., Ltd. Primary endpoints: Adverse Events at 52 weeks, Serious Adverse Events at 52 weeks and 1 more. Started Oct 2023; status: active, not recruiting.
02
Drugs
KH631
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT05657301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05657301.